Brief: Celyad Oncology: CYAD-211 Phase 1 Immunicy-1 Trial Data
13/05/2021 07:03
May 13 (Reuters) - CELYAD ONCOLOGY CYAD.BR :
* ANNOUNCED ON WEDNESDAY IT WAS TO PRESENT DATA FROM PHASE 1
IMMUNICY-1 TRIAL OF NON-GENE EDITED ALLOGENEIC CAR T CANDIDATE
CYAD-211 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AT EUROPEAN
HEMATOLOGY ASSOCIATION VIRTUAL CONGRESS
* NO GRADE ≥ 3 TREATMENT-RELATED ADVERSE EVENTS NOR EVIDENCE
OF
GRAFT-VERSUS-HOST DISEASE REPORTED FROM COMPLETED 1ST DOSE-LEVEL
(DL1) COHORT OF PHASE 1 DOSE-ESCALATION IMMUNICY-1 TRIAL
EVALUATING SHRNA-BASED ANTI-BCMA CAR T CANDIDATE, CYAD-211, FOR
RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA
* INITIAL CLINICAL ACTIVITY OBSERVED, WITH ONE CONFIRMED
PARTIAL
RESPONSE (PR) OBSERVED IN THIS LOW DOSE (30X106 CELLS PER
INFUSION)
Source text for Eikon: urn:newsml:reuters.com:*:nBw8grVHfa
Further company coverage: CYAD.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00))